Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA3 | P07451 | 3/20 | 0.39 |
| ▸ | CA4 | P22748 | 3/20 | 0.39 |
| ▸ | CA6 | P23280 | 3/20 | 0.39 |
| ▸ | CA5A | P35218 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HTR1E | P28566 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235660 | 0.79 | ALDH1A1 (0.41) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL1769275 | 0.79 | POLB (0.39) | CA12CA1CA2CA3CA4 | |
| SCHEMBL3229047 | 0.78 | NPC1 (0.40) | KCNJ1KCNH2MAPTHTR1ENPSR1 | |
| SCHEMBL3237033 | 0.78 | TSHR (0.44) | CA1CA2MAPTHTR1ENPSR1 | |
| SCHEMBL14176144 | 0.74 | ATM (0.49) | CA1CA2ICMTMAPTHTR1E | |
| SCHEMBL9110057 | 0.73 | HSD17B10 (0.48) | MAPTHTR1ENPSR1S1PR3ACHE | |
| SCHEMBL2817503 | 0.70 | MAOA (0.52) | CA12CA1CA2CA3CA4 | |
| SCHEMBL1769433 | 0.70 | TSHR (0.47) | CA1CA2MAPTHTR1ENPSR1 | |
| SCHEMBL5366727 | 0.70 | MAPT (0.43) | MAPTHTR1ENPSR1S1PR3LMNA | |
| SCHEMBL26218806 | 0.70 | MAPT (0.49) | MAPTHTR1ENPSR1S1PR3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | GATAD2B, GATAD2A, RUNX1 | CA12 3774/4885CA1 3986/4885CA2 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.